Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04163900 · ClinicalTrials.gov registry record · Phase 3
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
A Phase 3 study, sponsored by NuCana.
- Terminated
- Registry status
- Phase 3
- Development phase
- 773
- Enrollment target
NCT04163900 is a Phase 3 study that was terminated before completion, run by NuCana. The registered enrollment target is 773 participants.
The verdict
NCT04163900, a Phase 3 study, was terminated before completion, sponsored by NuCana.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 773 participants
- Enrollment target
Study Summary
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: * The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care * The combination of NUC-1031 plus cisplatin increases overall response rate compared to the gemcitabine plus cisplatin standard of care
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG NUC-1031
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 773 participants |
| Start Date | 2019-12-24 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04163900
The ClinicalTrials.gov registry entry for NCT04163900 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 773 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NuCana, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT04163900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04163900 about?
NCT04163900 is a clinical study titled "Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer". NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: * The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin stan...
What is the current status of trial NCT04163900?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 773 participants. The study started on 2019-12-24. Estimated completion is 2022-04-05.
What interventions are being tested in trial NCT04163900?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), NUC-1031 (DRUG).
Who is sponsoring clinical trial NCT04163900?
This trial is sponsored by NuCana, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.